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definitive RT, with or without concurrent chemotherapy, for head and 
neck cancer. Sixteen patients had FMISO PET scans in week 3 of RT 
and 14 completed a third scan upon completion of therapy. Maximum 
standard uptake values (SUVmax) and tumour-to-normal ratios (TNR) on 
the FMISO PET scans were measured as indictors of hypoxia. All 
patients underwent an 18Fluorodeoxyglucose (FDG) PET prior to 
commencing therapy and 14 had an FDG PET at 12 weeks post 
completion of RT. Median follow-up was 62 months with a minimum of 
58 months in surviving patients. 
Results: Twenty-seven FMISO avid lesions were detected. No local 
failures were observed in 14 lesions with an FMISO TNR 1.3 (61.5% vs. 
100%, p = 0.016). Overall survival (OS) at 5 years was poorer in 
patients with a FMISO TNR lesion of >1.3 (27.3% vs. 100%, p = 0.004) 
and a trend towards worse disease specific survival (DSS) (63.6% vs. 
100%, p = 0.12) was observed in this group. Complete resolution of 
FMISO uptake was seen in 14 patients, with 85% resolving before 
receiving 30 Gy. This was not associated with improved LC, DSS or OS 
nor was complete metabolic response on FDG PET, which occurred in 
71.4% of patients. FMISO SUVmax was not significantly associated with 
patient outcomes. 
Conclusions: Pre-radiotherapy FMISO PET is predictive for poor 
patient outcomes at 5 years, despite apparent disease response on 
serial functional imaging. FMISO PET has the potential utility for risk 
stratification and also provides valuable spatial information regarding 
patterns of failure and warrants further clinical evaluation. 
   
OC-0326   
Coregistration of 18F-FAZA- and 18F-FDG-PET in NSCLC 
V.R. Bollineni1, G.S.M.A. Kerner2, J. Pruim3, R.J.H.M. Steenbakkers1, 
M.J.B. Koole3, J. Widder1, H.J.M. Groen2, J.A. Langendijk1 
1University Medical Center Groningen / University of Groningen, 
Radiotherapy, Groningen, The Netherlands  
2University Medical Center Groningen / University of Groningen, 
Pulmonology, Groningen, The Netherlands  
3University Medical Center Groningen / University of Groningen, 
Nuclear Medicine and Molecular Imaging, Groningen, The Netherlands  
 
Purpose/Objective: Tumour hypoxia hampers the efficacy of 
radiotherapy (RT) due to increased radioresistance. Tumour hypoxia 
can be visualized by PET using hypoxia tracers like 18F-FAZA. However, 
previous studies showed that high 18F-FDG uptake is also associated 
with hypoxia. In this respect, the question arises as to whether 18F-
FDG and 18F-FAZA uptake show high spatial correlation or provide 
complimentary information that can be used for RT treatment 
optimization strategies. Therefore, the aim of the present study was: 
(1) to quantify tumour hypoxia using 18F-FAZA-PET,and: (2) to 
investigate the spatial 18F-FAZA-uptake in relation to 18F-FDG-uptake. 
Materials and Methods: Eleven patients with stage III or IV NSCLC 
underwent 18F-FDG and 18F-FAZA-PETprior to chemo(radio)therapy. To 
depict 18F-FDG uptake, the maximum standardized uptake value 
(SUVmax) was used, whereas to quantify hypoxia, the tumor-to-
background ratio (T/B ratio) was used and the percentage of tumour 
exhibiting a fractional hypoxic volume (FHV) > 1.4 was assessed. Both 
PET scans were made in treatment position. To enable spatial 
correlation between 18F-FDG and 18F-FAZA scans, voxel based analysis 
of respective uptake values employing deformable image registration 
was performed. 
Results: All eleven patients showed clear uptake of 18F-FAZA in the 
primary tumour. No significant correlation was observed between 18F-
FDG-SUVmax and the 18F-FAZA-T/B ratio. The median FHV 1.4 was 
48.4% (range5.0-91.5). Neither lesion size nor 18F-FDG SUVmax 
significantly correlated with FHV, whereas a significant correlation 
between 18F-FDGSUVmax and lesion size (r = 0.82; P = 0.002) was 
observed. The pattern of uptake of 18F-FAZA varied widely among 
tumours and was more heterogeneous compared to uptake of 18F-FDG, 
resulting in different spatial distribution patterns (Fig 1). Inmost 
patients, there was a trend towards higher 18F-FAZA-uptake with 
increasing uptake of 18F-FDG. In some patients (panel A), well 
demarcated high uptake areas of 18F-FAZA were observed within 
metabolically active tumour volumes, indicating local hypoxic 
subareas in tumours with high metabolic activity. In other patients, 
18F-FAZA and 18F-FDG were more diffuse and did not correlate at all 
(panel B), indicating a more heterogeneous distribution of hypoxia 
throughout the entire tumour. 
 
Conclusions: 18F-FDG and 18F-FAZA-PETdata provide independent 
information about tumor metabolism. Addition of 18F-FAZA-PET to 18F-
FDG-PET imaging may direct the choice of hypoxia-directed RT 
treatment planning in NSCLC. 
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Purpose/Objective: FDG based metrics of the primary tumor at 
baseline PET images have been found predictive for overall survival in 
NSCLC patients. In this study the predictive power of advanced 
metabolic metrics derived from baseline PET images were compared 
against those already widely used, as maximum and mean uptake, and 
GTV. With this approach we aim to improve the existing predictors of 
outcome, allowing the implementation of decision support-based 
individualized care systems (www.predictcancer.org). 
Materials and Methods: In the context of a prospective study 
(NCT01302626), 197 NSCLC patients, stages I-III, treated with curative 
intent were included. Each patient underwent a precalibrated PET-CT 
scan before radiotherapy treatment. Primary GTV was delineated on 
CT by an experienced oncologist. PET images were normalized for SUV 
prior to analysis. We derived mean and maximum SUV, GTV and a set 
of metabolic features, quantified by an Intensity-Volume Histogram 
that summarizes into a single curve the spatial relation of tumor 
volume and SUV (Figure1): 
- Absolute/RelativeVolume above Absolute Intensity threshold – AVAI 
and RVAI 
- Absolute/RelativeVolume above Relative Intensity threshold – AVRI 
and RVRI 
- AbsoluteIntensity above Relative Volume threshold – AIRV 
AVAI and RVAI are built in steps of 0.5 (SUV) up to the maximum 
uptake (Figure 1B). Curves regarding relative quantities are built in 
steps of 10% (Figure 1 A and C). 
A Cox Proportional Hazard Regression was performed for overall 
survival. Performance was evaluated by the Concordance Index 
(probability of concordance between predicted and observed survival 
based on pairs of individuals: C-index). The proportional hazards 
assumption was checked by the Scaled Schoenfeld residuals by 
entering interaction terms with (log)time in the model. All statistical 
methods were applied with R (version 2.15.0). 
 
 
